Table 3 Subgroup analysis
Outcomes | Group | RR (95% CI) | P value | P value for heterogeneity |
|---|---|---|---|---|
Resectability | Country | |||
Asian | 1.23 (1.04–1.46) | 0.015 | 0.243 | |
Europe | 1.00 (0.91–1.11) | 0.950 | 0.008 | |
Mean age (years) | ||||
60 or more | 1.02 (0.81–1.29) | 0.842 | 0.002 | |
< 60 | 1.29 (0.84–1.97) | 0.251 | < 0.001 | |
Percentage male (%) | ||||
70 or greater | 1.13 (0.87–1.46) | 0.355 | < 0.001 | |
< 70 | 1.14 (0.91–1.42) | 0.257 | 0.020 | |
Percentage of tumor stage (I and II) (%) | ||||
30 or greater | 0.99 (0.83–1.18) | 0.934 | 0.009 | |
< 30 | 1.22 (0.94–1.59) | 0.132 | 0.001 | |
Disease status | ||||
Gastroesophageal cancer | 1.02 (0.81–1.29) | 0.842 | 0.002 | |
Gastric cancer | 1.12 (0.96–1.31) | 0.136 | 0.018 | |
OS | Country | |||
Asian | – | – | – | |
Europe | 0.74 (0.63–0.88) | 0.001 | 0.792 | |
Mean age (years) | ||||
60 or more | 0.73 (0.61–0.88) | 0.001 | 0.674 | |
< 60 | 0.84 (0.52–1.35) | 0.474 | – | |
Percentage male (%) | ||||
70 or greater | 0.73 (0.61–0.88) | 0.001 | 0.674 | |
< 70 | 0.84 (0.52–1.35) | 0.474 | – | |
Percentage of tumor stage (I and II) (%) | ||||
30 or greater | 0.73 (0.61–0.88) | 0.001 | 0.674 | |
< 30 | 0.84 (0.52–1.35) | 0.474 | – | |
Disease status | ||||
Gastroesophageal cancer | 0.73 (0.61–0.88) | 0.001 | 0.674 | |
Gastric cancer | 0.84 (0.52–1.35) | 0.474 | – | |
PFS | Country | |||
Asian | – | – | – | |
Europe | 0.67 (0.57–0.79) | < 0.001 | 0.825 | |
Mean age (years) | ||||
60 or more | 0.66 (0.55–0.78) | < 0.001 | 0.936 | |
< 60 | 0.76 (0.49–1.17) | 0.212 | – | |
Percentage male (%) | ||||
70 or greater | 0.66 (0.55–0.78) | < 0.001 | 0.936 | |
< 70 | 0.76 (0.49–1.17) | 0.212 | – | |
Percentage of tumor stage (I and II) (%) | ||||
30 or greater | 0.66 (0.55–0.78) | < 0.001 | 0.936 | |
< 30 | 0.76 (0.49–1.17) | 0.212 | – | |
Disease status | ||||
Gastroesophageal cancer | 0.66 (0.55–0.78) | < 0.001 | 0.936 | |
Gastric cancer | 0.76 (0.49–1.17) | 0.212 | – | |